Company news

Travere Therapeutics, Inc. news in 2025

Travere Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

November 5, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2025

Travere Therapeutics Reports Third Quarter 2025 Financial Results

October 29, 2025

Travere Therapeutics to Report Third Quarter 2025 Financial Results

October 22, 2025

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

October 16, 2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

September 25, 2025

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

September 9, 2025

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

September 2, 2025

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

August 26, 2025

Travere Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025

Travere Therapeutics to Report Second Quarter 2025 Financial Results

July 29, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

June 10, 2025

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

June 9, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

June 2, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

May 22, 2025

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 14, 2025

Travere Therapeutics Reports First Quarter 2025 Financial Results

April 30, 2025

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

April 28, 2025

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

April 28, 2025

Travere Therapeutics to Report First Quarter 2025 Financial Results

April 23, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

March 30, 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

March 16, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 19, 2025

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

February 10, 2025

Travere Therapeutics Provides Corporate Update and 2025 Outlook

January 12, 2025

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025